Drug and disease signature integration identifies synergistic combinations in glioblastoma

Glioblastoma (GBM) is the most common primary adult brain tumor. Despite extensive efforts, the median survival for GBM patients is approximately 14 months. GBM therapy could benefit greatly from patient-specific targeted therapies that maximize treatment efficacy. Here we report a platform termed S...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Nat Commun
Autors principals: Stathias, Vasileios, Jermakowicz, Anna M., Maloof, Marie E., Forlin, Michele, Walters, Winston, Suter, Robert K., Durante, Michael A., Williams, Sion L., Harbour, J. William, Volmar, Claude-Henry, Lyons, Nicholas J., Wahlestedt, Claes, Graham, Regina M., Ivan, Michael E., Komotar, Ricardo J., Sarkaria, Jann N., Subramanian, Aravind, Golub, Todd R., Schürer, Stephan C., Ayad, Nagi G.
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6294341/
https://ncbi.nlm.nih.gov/pubmed/30552330
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-018-07659-z
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars